Immunotherapy drugs show major progress in early-stage cancer
SOUTH-EAST ASIA (Bloomberg): Drugs that boost the body's immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer.
Immunotherapy treatments such as Opdivo from Bristol Myers Squibb Co., Imfinzi from AstraZeneca PLC, and Roche Holding AG's Tecentriq have become bestsellers by increasing survival times in a number of advanced cancers.
Now the treatments are showing success against early and mid-stage cancers, according to results of large trials being presented at the American Society of Clinical Oncology meeting in Chicago this weekend. One highlight is that the drugs are preventing recurrences in operable tumors that are at high risk of relapsing.
"We're learning that immunotherapy may, in fact, be more effective when you have less of a tumor burden,' said Jean Bourhis, an oncologist at Lausanne University Hospital in Switzerland, who led a study on patients with squamous cell carcinoma of the head and neck. "The key is using it earlier.'
Treatment for that kind of head and neck cancer hasn't fundamentally changed in two decades. Use of Bristol's Opdivo in the study slashed the recurrence rate by nearly a quarter after three years when used after surgery to help prevent a relapse.
This development could impact about 40% of people diagnosed with the disease, Bourhis said.
In a study sponsored by AstraZeneca, researchers found that using the firm's Imfinzi drug before and after surgery reduced the odds by 29% over a two-year period that a nasty type of operable gastric or gastroesophageal junction cancer would relapse or progress.
The development sets the stage for a new global standard of care for such cancers, which are particularly common in Asia, doctors said.
Significantly Bolstered
In a study on colon cancer, sponsored by the National Cancer Institute, oncologists found that adding Roche's Tecentriq to standard chemotherapy used after surgery significantly bolstered the number of patients who were alive and disease free after three years.
The finding represents a major advance in the field, the study's lead investigator said, and could help roughly 15% of patients with operable colon cancer that has spread to the lymph nodes.
"We have a real potential to cure many of these patients,' the investigator, Mayo Clinic oncologist Frank Sinicrope, said in an interview.
For the companies, expanding the use of immune drugs to earlier stage cancers may provide a new source of revenue to an aging group of blockbusters.
"This brings a commercial opportunity,' said Susan Galbraith, AstraZeneca's executive vice president for oncology research. The company has discussed with regulators the potential for the drug to get approved for the new use case, she said, declining to go into detail of where those talks stood.
Merck & Co.'s immunotherapy Keytruda, which is featured in multiple studies at ASCO, shows how lucrative treating disease early can be. It has become the world's best-selling medicine thanks in part to its use in early cancer. Of the drug's 41 approved uses, nine are now for early-stage disease.
Treating cancer early is "where our growth is,' Dean Li, head of research at Merck, said Thursday at an investor conference. "But it's not just economic growth. This is where you can cure patients.'
Upending Medicine
New immunotherapy results in head and neck cancer are poised to upend decades of medical practice. For patients with an aggressive form of head and neck cancer, the longstanding first-line treatment was to surgically remove the tumor and use chemotherapy and radiation to keep the disease at bay.
The Opdivo study showed that adding the drug to the standard of care cut the risk of cancer recurrence three years after treatment by 24%.
That finding comes on the heels of a successful head and neck study from Merck's rival Keytruda drug. In a big study presented in April, Keytruda reduced the risk of relapse when it was used both before and after surgery in head and neck patients. That potential new use is now under review by US regulators.
In AstraZeneca's study being presented at ASCO, using Imfinzi before and after surgery was able to increase the number of people alive without a recurrence or disease progression after two years to 67.4% from 58.5%.
"For patients facing a high risk of relapse, this brings new hope for long-term survival,' said Yelena Y. Janjigian, an oncologist at New York's Memorial Sloan Kettering Cancer Center, who was lead investigator on the study. "It is a pretty big deal.'
Will Murray, a 52-year-old retired New York police detective, discovered he had a tumor at the junction of his esophagus and stomach in April 2022. It was operable, but he was at high risk of relapse. In an interview, he said the high death rate from this type of cancer terrified him.
But Murray received one of the last spots in the AstraZeneca study and got into the immunotherapy arm. His tumor started shrinking even before the surgery. And since the operation, it hasn't come back, although he did suffer thyroid deficiency, a side effect of immune therapy drugs.
Murray now has to eat carefully and can't sleep flat due to the stomach operation, but he can mostly live a normal life, including taking long walks and going on trips with his girlfriend. He credits the immunotherapy treatment trial for helping keep his tumors at bay.
"It saved my life,' Murray said.
--With assistance from Danielle Chaves. -- ©2025 Bloomberg L.P.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
a day ago
- The Star
China's first foreign-owned hospital seeks medical tourists
Perennial General Hospital Tianjin. — Bloomberg Tianjin: A Singapore hospital operator wants more international patients to seek treatment at its new medical centre in China, as foreign healthcare providers eye medical tourism as a new growth area in the world's second-largest economy. Perennial Holdings Pte's US$139mil hospital opened earlier this year in the northern city of Tianjin, and is the first fully foreign-owned medical facility in the mainland. The hospital aims to derive 30% of its revenue during its first year of operation from patients visiting from Russia, the Middle East and South-East Asia – hoping China will become an emerging destination for medical tourism that can compete with established regional rivals Singapore, Thailand and Japan. Perennial's focus on luring overseas patients to Tianjin came after China last year moved to allow private hospitals to be fully owned by foreign entities, which had previously needed a Chinese business partner. China's health regulator has since encouraged the Tianjin facility to differentiate itself from the country's public hospitals, hospital president Daniel Liu said in an interview this week. 'Medical tourism has yet to become an industry in China, but it's showing promise. We hope to make the pie bigger,' he said. 'Some specialities in the Chinese healthcare system have grown in the past two decades, to a point that measures up to international standards.' Private healthcare providers have faced headwinds operating in China as the country's post-Covid economic slump weighed on their main clientele – expats and well-off domestic customers with commercial insurance coverage. Some private hospitals and clinics have closed shop in recent months, while others have had to lower their prices, according to local media. China can be appealing to medical tourists in part due to a speedier diagnosis and treatment process. — Bloomberg
The Star
4 days ago
- The Star
Google Deepmind CEO says global AI cooperation 'difficult'
Hassabis advocated for the implementation of 'smart, adaptable regulation' because 'it needs to kind of adapt to where the technology ends up going and what the problems end up being'. — Bloomberg LONDON: Artificial intelligence pioneer and head of Google's Deepmind, Demis Hassabis on June 2 said that greater international cooperation around AI regulation was needed but "difficult" to achieve "in today's geopolitical context". At a time when AI is being integrated across all industries, its uses have raised major ethical questions, from the spread of misinformation to its impact on employment, or the loss of technological control. At London's South by Southwest (SXSW) festival on Monday, Hassabis, who has won a Nobel Prize in Chemistry for his research on AI, also addressed the challenges that artificial general intelligence (AGI) – a technology that could match and even surpass human capability – would bring. "The most important thing is it's got to be some form of international cooperation because the technology is across all borders. It's going to get applied to all countries," Hassabis said. "Many, many countries are involved in researching or building data centres or hosting these technologies. So I think for anything to be meaningful, there has to be some sort of international cooperation or collaboration and unfortunately that's looking quite difficult in today's geopolitical context," he said. At Paris's AI summit in February, 58 countries – including China, France, India, the European Union and the African Union Commission – called for enhanced coordination on AI governance. But the US warned against "excessive regulation", with US Vice President JD Vance saying it could "kill a transformative sector". Alongside the US, the UK refused to sign the summit's appeal for an "open", "inclusive" and "ethical" AI. Hassabis on Monday advocated for the implementation of "smart, adaptable regulation" because "it needs to kind of adapt to where the technology ends up going and what the problems end up being". – AFP
The Star
6 days ago
- The Star
Immunotherapy drugs show major progress in early-stage cancer
SOUTH-EAST ASIA (Bloomberg): Drugs that boost the body's immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer. Immunotherapy treatments such as Opdivo from Bristol Myers Squibb Co., Imfinzi from AstraZeneca PLC, and Roche Holding AG's Tecentriq have become bestsellers by increasing survival times in a number of advanced cancers. Now the treatments are showing success against early and mid-stage cancers, according to results of large trials being presented at the American Society of Clinical Oncology meeting in Chicago this weekend. One highlight is that the drugs are preventing recurrences in operable tumors that are at high risk of relapsing. "We're learning that immunotherapy may, in fact, be more effective when you have less of a tumor burden,' said Jean Bourhis, an oncologist at Lausanne University Hospital in Switzerland, who led a study on patients with squamous cell carcinoma of the head and neck. "The key is using it earlier.' Treatment for that kind of head and neck cancer hasn't fundamentally changed in two decades. Use of Bristol's Opdivo in the study slashed the recurrence rate by nearly a quarter after three years when used after surgery to help prevent a relapse. This development could impact about 40% of people diagnosed with the disease, Bourhis said. In a study sponsored by AstraZeneca, researchers found that using the firm's Imfinzi drug before and after surgery reduced the odds by 29% over a two-year period that a nasty type of operable gastric or gastroesophageal junction cancer would relapse or progress. The development sets the stage for a new global standard of care for such cancers, which are particularly common in Asia, doctors said. Significantly Bolstered In a study on colon cancer, sponsored by the National Cancer Institute, oncologists found that adding Roche's Tecentriq to standard chemotherapy used after surgery significantly bolstered the number of patients who were alive and disease free after three years. The finding represents a major advance in the field, the study's lead investigator said, and could help roughly 15% of patients with operable colon cancer that has spread to the lymph nodes. "We have a real potential to cure many of these patients,' the investigator, Mayo Clinic oncologist Frank Sinicrope, said in an interview. For the companies, expanding the use of immune drugs to earlier stage cancers may provide a new source of revenue to an aging group of blockbusters. "This brings a commercial opportunity,' said Susan Galbraith, AstraZeneca's executive vice president for oncology research. The company has discussed with regulators the potential for the drug to get approved for the new use case, she said, declining to go into detail of where those talks stood. Merck & Co.'s immunotherapy Keytruda, which is featured in multiple studies at ASCO, shows how lucrative treating disease early can be. It has become the world's best-selling medicine thanks in part to its use in early cancer. Of the drug's 41 approved uses, nine are now for early-stage disease. Treating cancer early is "where our growth is,' Dean Li, head of research at Merck, said Thursday at an investor conference. "But it's not just economic growth. This is where you can cure patients.' Upending Medicine New immunotherapy results in head and neck cancer are poised to upend decades of medical practice. For patients with an aggressive form of head and neck cancer, the longstanding first-line treatment was to surgically remove the tumor and use chemotherapy and radiation to keep the disease at bay. The Opdivo study showed that adding the drug to the standard of care cut the risk of cancer recurrence three years after treatment by 24%. That finding comes on the heels of a successful head and neck study from Merck's rival Keytruda drug. In a big study presented in April, Keytruda reduced the risk of relapse when it was used both before and after surgery in head and neck patients. That potential new use is now under review by US regulators. In AstraZeneca's study being presented at ASCO, using Imfinzi before and after surgery was able to increase the number of people alive without a recurrence or disease progression after two years to 67.4% from 58.5%. "For patients facing a high risk of relapse, this brings new hope for long-term survival,' said Yelena Y. Janjigian, an oncologist at New York's Memorial Sloan Kettering Cancer Center, who was lead investigator on the study. "It is a pretty big deal.' Will Murray, a 52-year-old retired New York police detective, discovered he had a tumor at the junction of his esophagus and stomach in April 2022. It was operable, but he was at high risk of relapse. In an interview, he said the high death rate from this type of cancer terrified him. But Murray received one of the last spots in the AstraZeneca study and got into the immunotherapy arm. His tumor started shrinking even before the surgery. And since the operation, it hasn't come back, although he did suffer thyroid deficiency, a side effect of immune therapy drugs. Murray now has to eat carefully and can't sleep flat due to the stomach operation, but he can mostly live a normal life, including taking long walks and going on trips with his girlfriend. He credits the immunotherapy treatment trial for helping keep his tumors at bay. "It saved my life,' Murray said. --With assistance from Danielle Chaves. -- ©2025 Bloomberg L.P.
